Abbvie Inc (ABBV)

$232.91 -0.96 (-0.41%)
Market Cap 413.34B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 24.58
Forward PE 21.82
Profit Margin 7.59%
Debt to Equity Ratio -26.45
Volume 7,618,400
Avg Vol 6,104,634
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 72%
Beta 0.50
Analysts Strong Sell
Price Target $244.54

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
SuperGreenToday
SuperGreenToday Nov. 20 at 9:53 AM
$ABBV Share Price: $232.83 Contract Selected: Dec 12, 2025 $235 Calls Buy Zone: $3.53 – $4.36 Target Zone: $6.26 – $7.65 Potential Upside: 68% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 20 at 6:56 AM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $232.50 Put · NOV 28, 2025 Exp Entry Price: $3.54 - $3.72 Exit Price Target: $7.26 Profit Margin: +105% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 20 at 6:09 AM
💎 LiquidTheta® Live Actionable Trade Asset: $ABBV Contracts: $ABBV December 18, 2026 $240 Calls Scale in: $20.81- $25.44 Scale out: $80.94-$138.75 Profit Potential : 268% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
RunnerSignals
RunnerSignals Nov. 20 at 4:34 AM
$ABBV slow and steady wins. the long-term compounding story stays intact. dips still look like accumulation zones for patient traders
0 · Reply
Iightning
Iightning Nov. 19 at 8:47 PM
1ightning® Options Trade Alert (Actionable) | Buy $ABBV Dec 5 $235 Call | Enter: $4.86 Exit: $6.90 | Profit: 41.91% ROI | https://1ightning.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 19 at 8:43 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $230.00 Put · NOV 28, 2025 Exp Entry Price: $2.95 - $3.05 Exit Price Target: $5.72 Profit Margin: +94% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 19 at 6:41 PM
$SLS The Aza+VEN Viale-M - AML Maintenance Phase 3 Trial for Primary Remission Patients CR1, conducted by $ABBV $RHHBY and $BMY FAILED. It was a 2 Part Trial, initial stage to identify ideal dosing, with multiple options, - failed to find a non toxic dose of Aza+VEN Oral too, for AML CR1 Maintenance. Aza+VEN is the BAT / Best Available Treatment for the REGAL Control Arm AML CR2 Patients. Meanwhile we are seeing near Miraculous Survival in the ALL Pooled Data. . . .
0 · Reply
LionsFan777
LionsFan777 Nov. 19 at 3:28 PM
$ABBV, $AVGO, $TSLA Nice morning !
0 · Reply
ZacksResearch
ZacksResearch Nov. 19 at 2:11 PM
$ABBV is bouncing back — but is this rebound strong enough to trust? The teaser shows the stock recovering from its Q3 dip as immunology and neuroscience strength help counter Humira erosion and softness in aesthetics. A real push-pull setup for investors. Full buy/hold/sell breakdown here 👉 https://www.zacks.com/stock/news/2792944/abbvie-stock-rebounds-after-q3-dip-time-to-buy-hold-or-sell?cid=sm-stocktwits-2-2792944-teaser-21586&ADID=SYND_STOCKTWITS_TWEET_2_2792944_TEASER_21586
0 · Reply
ZacksResearch
ZacksResearch Nov. 19 at 1:11 PM
$ABBV: Is the recent surge a buying signal or a false dawn? 📈 🔥 Sales rose 9.1% in Q3 2025, and the company raised 2025 guidance for the third time, driven by Skyrizi and Rinvoq's stellar performance. Yet, stock dipped post-earnings due to softer oncology sales and continued aesthetics weakness. Discover if ABBV's momentum can continue 👉 https://www.zacks.com/stock/news/2792944/abbvie-stock-rebounds-after-q3-dip-time-to-buy-hold-or-sell?cid=sm-stocktwits-2-2792944-body-21584&ADID=SYND_STOCKTWITS_TWEET_2_2792944_BODY_21584
0 · Reply
Latest News on ABBV
AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

Nov 18, 2025, 12:47 PM EST - 1 day ago

AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

It's Best Time In 10 Years To Lock In Income: Our Picks

Nov 18, 2025, 9:00 AM EST - 2 days ago

It's Best Time In 10 Years To Lock In Income: Our Picks

ADC AVGO DG ENB EPD FDX MSFT

Global drugmakers rush to boost US presence as tariff threat looms

Nov 18, 2025, 8:25 AM EST - 2 days ago

Global drugmakers rush to boost US presence as tariff threat looms

AMGN AZN BIIB GILD GSK JNJ LLY

AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript

Nov 14, 2025, 4:31 PM EST - 5 days ago

AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

Nov 14, 2025, 3:19 PM EST - 5 days ago

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

AZN JNJ LLY MRK NVO PFE XLV

AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™

Nov 13, 2025, 8:30 AM EST - 7 days ago

AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™

AbbVie Shares Rise To Intraday High After Key Trading Signal

Nov 12, 2025, 3:06 PM EST - 7 days ago

AbbVie Shares Rise To Intraday High After Key Trading Signal

Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

Nov 12, 2025, 8:30 AM EST - 8 days ago

Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence

Nov 12, 2025, 8:30 AM EST - 8 days ago

Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence

AbbVie Has Many Bullish Attributes (Technical Analysis)

Nov 11, 2025, 10:40 PM EST - 8 days ago

AbbVie Has Many Bullish Attributes (Technical Analysis)

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

Nov 8, 2025, 6:38 AM EST - 12 days ago

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

PFE

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 16 days ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ALNY AMGN BMY LLY MBX MDGL MEDI

ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November

Nov 1, 2025, 11:15 PM EDT - 18 days ago

ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November

ADP AEP AIZ AOS ATO BDX BRO

Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 19 days ago

Best Dividend Aristocrats For November 2025

ABT ADM ADP AMCR AOS ATO BDX

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

Oct 31, 2025, 3:56 PM EDT - 19 days ago

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

Oct 31, 2025, 11:47 AM EDT - 19 days ago

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

AbbVie: Why Q3 Confirms Its Immunology Dominance

Oct 31, 2025, 10:39 AM EDT - 19 days ago

AbbVie: Why Q3 Confirms Its Immunology Dominance

AbbVie Lifts Profit Outlook as Sales Rise

Oct 31, 2025, 8:42 AM EDT - 20 days ago

AbbVie Lifts Profit Outlook as Sales Rise

AbbVie Beats Third-Quarter Estimates. There's More to the Drugmaker's Earnings.

Oct 31, 2025, 8:20 AM EDT - 20 days ago

AbbVie Beats Third-Quarter Estimates. There's More to the Drugmaker's Earnings.

AbbVie lifts annual profit forecast on resilient demand for newer immunology drugs

Oct 31, 2025, 7:54 AM EDT - 20 days ago

AbbVie lifts annual profit forecast on resilient demand for newer immunology drugs

AbbVie Reports Third-Quarter 2025 Financial Results

Oct 31, 2025, 7:49 AM EDT - 20 days ago

AbbVie Reports Third-Quarter 2025 Financial Results

The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year

Oct 29, 2025, 5:00 PM EDT - 21 days ago

The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year

AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo

Oct 29, 2025, 8:11 AM EDT - 22 days ago

AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo

Best Dividend Kings: October 2025

Oct 29, 2025, 5:11 AM EDT - 22 days ago

Best Dividend Kings: October 2025

ABM ABT ADM ADP AWR BDX BKH

AbbVie: Deep Discount Before Earnings

Oct 28, 2025, 11:28 AM EDT - 22 days ago

AbbVie: Deep Discount Before Earnings

Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings

Oct 28, 2025, 10:40 AM EDT - 22 days ago

Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings

GILD LLY MRK

Final Trades: Abbvie, Qualcomm, Aptiv, and Palo Alto Networks

Oct 21, 2025, 2:27 PM EDT - 4 weeks ago

Final Trades: Abbvie, Qualcomm, Aptiv, and Palo Alto Networks

APTV PANW QCOM

The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients

Oct 21, 2025, 8:00 AM EDT - 4 weeks ago

The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients

AbbVie's Rinvoq shows superiority over Humira in head-to-head study

Oct 20, 2025, 8:12 AM EDT - 4 weeks ago

AbbVie's Rinvoq shows superiority over Humira in head-to-head study

RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor

Oct 20, 2025, 8:00 AM EDT - 4 weeks ago

RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor

AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition

Oct 17, 2025, 4:34 PM EDT - 4 weeks ago

AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition

AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin

Oct 17, 2025, 9:00 AM EDT - 4 weeks ago

AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin

Final Trades: Abbvie, Amazon, Datadog and Sixth Street Specialty Lending

Oct 13, 2025, 1:28 PM EDT - 5 weeks ago

Final Trades: Abbvie, Amazon, Datadog and Sixth Street Specialty Lending

AMZN DDOG TSLX

U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease

Oct 13, 2025, 10:57 AM EDT - 5 weeks ago

U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease

AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

Oct 13, 2025, 7:15 AM EDT - 5 weeks ago

AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer

Oct 9, 2025, 8:00 AM EDT - 6 weeks ago

SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 6 weeks ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ALVO AMGN ARKG AZN BIIB BMY GILD

AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor

Oct 6, 2025, 9:00 AM EDT - 6 weeks ago

AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor

AbbVie expects $2.7 billion R&D charge in third quarter

Oct 3, 2025, 4:16 PM EDT - 6 weeks ago

AbbVie expects $2.7 billion R&D charge in third quarter

AbbVie: Wins Accumulating While We Wait For Next BD Steps

Oct 3, 2025, 11:05 AM EDT - 6 weeks ago

AbbVie: Wins Accumulating While We Wait For Next BD Steps

ABBV Stock vs. Eli Lilly & Merck

Oct 2, 2025, 8:20 AM EDT - 7 weeks ago

ABBV Stock vs. Eli Lilly & Merck

LLY MRK

AbbVie to Host Third-Quarter 2025 Earnings Conference Call

Oct 2, 2025, 8:00 AM EDT - 7 weeks ago

AbbVie to Host Third-Quarter 2025 Earnings Conference Call

Natrelle® Awarded Supplier Agreement from Vizient

Oct 1, 2025, 8:00 AM EDT - 7 weeks ago

Natrelle® Awarded Supplier Agreement from Vizient

AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.

Sep 30, 2025, 3:00 PM EDT - 7 weeks ago

AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.

AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options

Sep 30, 2025, 8:00 AM EDT - 7 weeks ago

AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Sep 29, 2025, 7:30 PM EDT - 7 weeks ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility

Sep 29, 2025, 12:00 PM EDT - 7 weeks ago

AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility

AbbVie to launch ovarian cancer drug in UK at the same list price as US

Sep 29, 2025, 9:11 AM EDT - 7 weeks ago

AbbVie to launch ovarian cancer drug in UK at the same list price as US

AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)

Sep 29, 2025, 9:00 AM EDT - 7 weeks ago

AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)

AbbVie For Healthy Dividend Growth

Sep 27, 2025, 7:00 AM EDT - 7 weeks ago

AbbVie For Healthy Dividend Growth

SuperGreenToday
SuperGreenToday Nov. 20 at 9:53 AM
$ABBV Share Price: $232.83 Contract Selected: Dec 12, 2025 $235 Calls Buy Zone: $3.53 – $4.36 Target Zone: $6.26 – $7.65 Potential Upside: 68% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 20 at 6:56 AM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $232.50 Put · NOV 28, 2025 Exp Entry Price: $3.54 - $3.72 Exit Price Target: $7.26 Profit Margin: +105% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 20 at 6:09 AM
💎 LiquidTheta® Live Actionable Trade Asset: $ABBV Contracts: $ABBV December 18, 2026 $240 Calls Scale in: $20.81- $25.44 Scale out: $80.94-$138.75 Profit Potential : 268% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
RunnerSignals
RunnerSignals Nov. 20 at 4:34 AM
$ABBV slow and steady wins. the long-term compounding story stays intact. dips still look like accumulation zones for patient traders
0 · Reply
Iightning
Iightning Nov. 19 at 8:47 PM
1ightning® Options Trade Alert (Actionable) | Buy $ABBV Dec 5 $235 Call | Enter: $4.86 Exit: $6.90 | Profit: 41.91% ROI | https://1ightning.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 19 at 8:43 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $230.00 Put · NOV 28, 2025 Exp Entry Price: $2.95 - $3.05 Exit Price Target: $5.72 Profit Margin: +94% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 19 at 6:41 PM
$SLS The Aza+VEN Viale-M - AML Maintenance Phase 3 Trial for Primary Remission Patients CR1, conducted by $ABBV $RHHBY and $BMY FAILED. It was a 2 Part Trial, initial stage to identify ideal dosing, with multiple options, - failed to find a non toxic dose of Aza+VEN Oral too, for AML CR1 Maintenance. Aza+VEN is the BAT / Best Available Treatment for the REGAL Control Arm AML CR2 Patients. Meanwhile we are seeing near Miraculous Survival in the ALL Pooled Data. . . .
0 · Reply
LionsFan777
LionsFan777 Nov. 19 at 3:28 PM
$ABBV, $AVGO, $TSLA Nice morning !
0 · Reply
ZacksResearch
ZacksResearch Nov. 19 at 2:11 PM
$ABBV is bouncing back — but is this rebound strong enough to trust? The teaser shows the stock recovering from its Q3 dip as immunology and neuroscience strength help counter Humira erosion and softness in aesthetics. A real push-pull setup for investors. Full buy/hold/sell breakdown here 👉 https://www.zacks.com/stock/news/2792944/abbvie-stock-rebounds-after-q3-dip-time-to-buy-hold-or-sell?cid=sm-stocktwits-2-2792944-teaser-21586&ADID=SYND_STOCKTWITS_TWEET_2_2792944_TEASER_21586
0 · Reply
ZacksResearch
ZacksResearch Nov. 19 at 1:11 PM
$ABBV: Is the recent surge a buying signal or a false dawn? 📈 🔥 Sales rose 9.1% in Q3 2025, and the company raised 2025 guidance for the third time, driven by Skyrizi and Rinvoq's stellar performance. Yet, stock dipped post-earnings due to softer oncology sales and continued aesthetics weakness. Discover if ABBV's momentum can continue 👉 https://www.zacks.com/stock/news/2792944/abbvie-stock-rebounds-after-q3-dip-time-to-buy-hold-or-sell?cid=sm-stocktwits-2-2792944-body-21584&ADID=SYND_STOCKTWITS_TWEET_2_2792944_BODY_21584
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 19 at 7:20 AM
💎 LiquidTheta® Live Actionable Trade Asset: $ABBV Contracts: $ABBV December 18, 2026 $240 Calls Scale in: $21.43- $26.19 Scale out: $83.34-$142.88 Profit Potential : 399% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
Iightning
Iightning Nov. 19 at 5:19 AM
1ightning® Options Trade Alert (Actionable) | Buy $ABBV Dec 5 $235 Call | Enter: $4.86 Exit: $6.90 | Profit: 41.91% ROI | https://1ightning.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 19 at 2:51 AM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $232.50 Put · NOV 28, 2025 Exp Entry Price: $2.47 - $3.40 Exit Price Target: $4.35 Profit Margin: +76% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 18 at 9:42 PM
$SLS FACTS: BAT for Control ARM patients Failed 3 Large Phase 3 Trials conducted by $ABBV $RHHBY $BMY - GPs Achieved Statistically Significant 21 Month MOS - in an older (74), All MRD+ (Sicker) Phase 2 Trial Setting. Gps Phase Patients will also recieve 15 treatments in year 1 and 6 in year 2 and 4 in year 3 and beyond vs only 6-12 in year 1 in the P2. GPS Elicited a 64% Immune Response rate in the P2, its 80% in the P3 per the IDMC unblinded Interim Data. Ir is Directly Correlated with increased Survival. -- GPS P 3 Patients will have a Longer MOS than the 21 month P2. - IDMC unblinded P3 Interim ALL Pooled n.y.m >13.5. - 128 P3 Enrollment Completed 20 months ago 105 of the 128 Enrolled Nov 2023 are in Trial AT Least 24 months. - There are several Published AML CR2 Trial Results for BAT, w NIL Surviving Past 20 months - only the rarest of rare Control Arm patients on BAT Remain Alive past 20 months. There +/- 60 Patient EVENTS Just from the Control ARM and we have yet to See 80. ...
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 18 at 9:39 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $232.50 Put · NOV 28, 2025 Exp Entry Price: $2.47 - $3.40 Exit Price Target: $4.35 Profit Margin: +76% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Iightning
Iightning Nov. 18 at 9:15 PM
1ightning® Options Trade Alert (Actionable) | Buy $ABBV Nov 28 $230 Call | Enter: $2.24 Exit: $2.89 | Profit: 29.23% ROI | https://1ightning.com
0 · Reply
Theflash88
Theflash88 Nov. 18 at 7:45 PM
$GILD $BMY $ABBV $MRK
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 18 at 6:56 PM
$SLS Everyone Does KNOW the Best Available Treatment - BAT - for Control ARM Patients - FAILED a Phase 3 Trial for AML Patients in First Remission - CR1. VIALE-M a Large Phase 3 Conducted by $ABBV $RHHBY and $BMY Failed in an AML Primary Remission CR1 Maintenance Setting. BAT for REGAL Control Arm Patients in AML CR2, Just Failed in CR1 --- HELLFǔCKINGLO!
1 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Nov. 18 at 5:51 PM
$ABBV FDA Approves Epcoritamab-bysp For Follicular Lymphoma Indications
0 · Reply
MahiMe
MahiMe Nov. 18 at 5:50 PM
$ABBV $ABBV AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma https://www.stocktitan.net/news/ABBV/abb-vie-announces-u-s-fda-approval-of-epkinly-epcoritamab-bysp-in-oiwfo65x8vx5.html
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Nov. 18 at 4:41 PM
$GMAB $ABBV
0 · Reply
LionsFan777
LionsFan777 Nov. 18 at 4:41 PM
$ABBV Holding on low volume. My target is $240-245.
0 · Reply